As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has ...

Vertex currently markets four cystic fibrosis (CF) products — Trikafta/Kaftrio, Symdeko (marketed as Symkevi in Europe), Orkambi and Kalydeco. Revenues in fourth-quarter 2023 are likely to have ...

Vertex Earnings: Robust Sales of Trikafta/Kaftrio Support Long-Term Growth and Diverse Pipeline Narrow-moat Vertex delivered solid third-quarter results, highlighted by a 12% increase in product ...

NHS England has agreed a deal with Vertex for its three-drug cystic fibrosis therapy Kaftrio, just days after the EMA’s human medicines committee recommended approval of the drug. The deal means ...

Nearly 93% of the company's sales come from its cystic fibrosis (CF) drug Trikafta/Kaftrio -- for now. The big biotech company is usually highly profitable. For example, Vertex reported earnings ...

which showed that treatment with once-daily Alyftrek enhanced patient benefit compared to Vertex’s blockbuster CF drug Trikafta (Kaftrio in Europe), which is required to be administered twice daily.

Total revenues rose 12% year over year, primarily driven by higher sales of Trikafta/Kaftrio (marketed as Kaftrio in Europe) in younger age groups. The company currently markets four CF products ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA ® (elexacaftor ...

The FDA's nod is based on late-stage data, which show that treatment with VRTX's Alyftrek enhances patient benefit compared ...